Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
About Adare PharmaceuticalsAdare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health. We have expertise in overcoming complex formulation challenges and adding valuable IP to new and existing products—resulting in medicines that deliver greater value to all stakeholders, while meeting the needs of patients. We have the ability to transform drug formulations using our proprietary technologies, developing novel Rx and OTC products. Adare is uniquely suited to unlock the potential of more medicines, helping patients to maximize the benefit of their treatments. We are committed to partnering with innovators in the pharmaceutical industry. Visit www.AdarePharma.com and experience a partnership that's truly transformative.
62 articles with Adare Pharmaceuticals
Adare Pharma Solutions, a technology-driven contract development and manufacturing organization, announced the acquisition of Frontida BioPharm, a vertically integrated CDMO focused on oral formulations.
Adare Pharma Solutions, a specialized Contract Development Manufacturing Organization, announced it has strengthened its executive leadership team with two key hires.
Adare Pharma Solutions is excited to announce that Ludger Roedder has joined the organization as President of Adare Biome.
Thomas H. Lee Partners, L.P. and Frazier Healthcare Partners announced they have acquired Adare Pharmaceuticals, which will be rebranded Adare Pharma Solutions, a leading specialty contract development and manufacturing organization and global provider of advanced pharmaceutical technologies, from TPG Capital.
May 4, 2020 12:00 UTC Kansas-based pharmaceutical technology company develops customized formulations and intellectual property Deal includes platforms that can be dosed in oral, injectable and otic (ear) formulations Acquisition expands Adare’s technology platforms and product development capabilities
Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy
Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. announced a collaboration to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder.
Adare Pharmaceuticals, Inc. announced that it has entered into an agreement with Egalet Corporation, to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property.
Lannett And Adare Enter Into Distribution Agreement For Dexmethylphenidate Hydrochloride Extended Release Capsules
Lannett Company, Inc. today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride Extended Release (ER) Capsules USP (CII), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg. Lannett expects to commence marketing within a few months.
5/13/2018Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
Robert J. Rush appointed Vice President, Finance and Chief Financial Officer; Ajay Damani appointed Vice President, Business Unit Leader – Pharmaceutical Technologies; Giuseppe Di Vincenzo named Vice President, Strategy
Adare Pharma Appoints Dr. Peter Richardson As Vice President, Research & Development And Chief Medical Officer
TPG Completes Acquisition of Aptalis Pharmaceutical Technologies, Company Renamed Adare Pharmaceuticals
Forest Laboratories, Inc. Sets $1.8 Billion High Yield Bond Deal To Back Aptalis Pharmaceutical Technologies Buy
Novamedica Signs Distribution Agreement With Aptalis Pharmaceutical Technologies To Develop And Commercialize Gastrointestinal Pharmaceutical Products In Russia